KBI: A CRO company specialized on NHP pharmacology services
Kunming Biomed International (KBI), located in southwest China, is a science-based CRO providing preclinical services specialized in non-human primates. The core competency of KBI is to provide NHP disease models to test drug candidates and medical devices for their pharmacological effects and biocompatible repairs. KBI also conducts adjacency studies in PK/PD, in vitro pharmacology, histology/pathology, and preliminary toxicology. KBI has already achieved AAALAC accreditation
Copyright 2014, a2z, Inc. All rights reserved.